1-Year outcomes of hypertension management in 13,000 outpatients under practice conditions: Prospective 3A registry

International Journal of Cardiology

Volumn 176, Issue 3, 2014, Pages 589-594

  Zeymer, Uwe ^a   Dechend, Ralf ^b   Riemer, Thomas ^a   Kaiser, Edelgard ^c   Senges, Jochen ^a   Pittrow, David ^d   Schmieder, Roland E ^e  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

^b HELIOS KLINIKUM BERLIN BUCH   (Germany)

^c NOVARTIS PHARMA GMBH   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^e UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Clinical practice; Control rates; Effectiveness; Essential hypertension; Long term; Management; Outcomes; Renin angiotensin system

Indexed keywords

ALISKIREN; AMIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUMARIC ACID DERIVATIVE;

AGED; FEMALE; GERMANY; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; PROSPECTIVE STUDY; REGISTER; TREATMENT OUTCOME;

AGED; AMIDES; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; FEMALE; FUMARATES; GERMANY; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; REGISTRIES; TREATMENT OUTCOME;

EID: 84908200376     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.07.089     Document Type: Article

References (32)

1. K. Wolf-Maier, R.S. Cooper, and J.R. Banegas Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States J Am Med Ass 289 2003 2363 2369
2. A. Sharma, H. Wittchen, and W. Kirch High prevalence and poor control of hypertension in primary care: cross-sectional study J Hypertens 22 2004 479 486
3. H. Löwel, C. Meisinger, M. Heier, H. Hymer, D. Alte, and H. Volzke Epidemiologie der arteriellen Hypertonie in Deutschland. Ausgewählte Ergebnisse bevölkerungsrepräsentativer Querschnittstudien Dtsch Med Wochenschr 131 2006 2586 2591
4. D. Pittrow, L. Pieper, J. Klotsche, and H. Wittchen DETECT. Ergebnisse einer klinisch-epidemiologischen Querschnitts- und Verlaufsstudie mit 50.000 Patienten in 3.000 Hausarztpraxen 2007 Elsevier München
5. M. Thoenes, U. Tebbe, and L. Rosin Blood pressure management in a cohort of hypertensive patients in Germany treated by cardiologists Clin Res Cardiol 100 2011 483 491
6. S. MacMahon, R. Peto, and J. Cutler Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias Lancet 335 1990 765 774
7. R. Jackson, C.M. Lawes, D.A. Bennett, R.J. Milne, and A. Rodgers Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk Lancet 365 2005 434 441
8. Blood Pressure Lowering Treatment Trialists Collaboration Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials Arch Intern Med 165 2005 1410 1419
9. M.R. Law, J.K. Morris, and N.J. Wald Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies BMJ 338 2009 b1665
10. G. Mancia, R. Fagard, and K. Narkiewicz 2013 ESH/ESC guidelines for the management of arterial hypertension Blood Press 31 2013 1281 1357
11. E.L. Hannan Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations J Am Coll Cardiol Intv 1 2008 211 217
12. R.B. D'Agostino Jr., and R.B. D'Agostino Sr. Estimating treatment effects using observational data JAMA 297 2007 314 316
13. J.S. Alpert Are data from clinical registries of any value? Eur Heart J 21 2000 1399 1401
14. A.K. Gitt, H. Bueno, and N. Danchin The role of cardiac registries in evidence-based medicine Eur Heart J 31 2010 525 529
15. D.A. Zarin, T. Tse, R.J. Williams, R.M. Califf, and N.C. Ide The ClinicalTrials.gov results database - update and key issues N Engl J Med 364 2011 852 860
16. U. Zeymer, R. Dechend, and E. Deeg Aliskiren for the treatment of essential hypertension under real-life practice conditions: design and baseline data of the prospective 3A registry Int J Clin Pract 66 2012 251 261
17. Verband der forschenden Arzneimittelhersteller (VfA) Registry of non-interventional studies (NIS): 3A register Internet: http://www.vfa.de/de/arzneimittel-forschung/datenbanken-zu-arzneimitteln/nisdb/nis-details/-616 [Last update 7. June 2011. Accessed on 9. October 2011]
18. Deutsche Hypertonie Gesellschaft - Deutsche Hochdruckliga e.V. (DHL) S2 guideline: treatment of arterial hypertension Bonn 34 2008 481 498 [Internet: http://www.awmf.org/uploads/tx-szleitlinien/046-001-S2-Behandlung-der-arteriellen-Hypertonie-06-2008-06-2013.pdf. Accessed on 27 October 2011]
19. U. Steckelings, M. Stoppelhaar, and A. Sharma HYDRA: possible determinants of unsatisfactory hypertension control in German primary care patients Blood Press 13 2004 80 88
20. D. Pittrow, W. Kirch, and P. Bramlage Patterns of antihypertensive drug utilization in primary care Eur J Clin Pharmacol 60 2004 135 142
21. S. Silber, B.M. Richartz, F. Goss, W. Haerer, M. Glowatzki, and R.E. Schmieder Care of hypertensive patients seen by cardiologists: results of the Snapshot Hypertension Registry Dtsch Med Wochenschr 132 2007 2430 2435
22. A. Muller, J. Schweizer, W. Kirch, and C. Schindler Current status of antihypertensive drug treatment in primary care practice at launch of the new renin inhibitor aliskiren (RASANT) Med Klin (Munich) 105 2010 155 162
23. M. Volpe, G. Tocci, and F. Bianchini Use of aliskiren in a 'real-life' model of hypertension management: analysis of national web-based drug-monitoring system in Italy J Hypertens 30 2012 194 203
24. P. de Cotret, A. Steele, J. Leclerc, M. Hubert, L. Tran, and R. Rigal Real-life blood pressure reductions in hypertension patients treated with aliskiren. Interim results of the Canadian Anchor registry (abstract 4A.05) Presentation at the European Society of Hypertension (ESH) Meeting. Milan 17-20 June 2011
25. L. Hansson, A. Zanchetti, and S. Carruthers Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT study group Lancet 351 1998 1755 1762
26. F. Ruschitzka Evidence for improvement in survival with antihypertensive combination treatment J Hypertens 29 Suppl. 1 2011 S9 S14
27. S. Czernichow, A. Zanchetti, and F. Turnbull The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials J Hypertens 29 2011 4 16
28. A.V. Chobanian, G.L. Bakris, and H.R. Black The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report JAMA 289 2003 2560 2571
29. G. Danaei, M.M. Finucane, and J.K. Lin National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants Lancet 377 2011 568 577
30. D.M. Lloyd-Jones, J.C. Evans, and D. Levy Hypertension in adults across the age spectrum: current outcomes and control in the community JAMA 294 2005 466 472
31. P.G. Steg, D.L. Bhatt, and P.W. Wilson One-year cardiovascular event rates in outpatients with atherothrombosis JAMA 297 2007 1197 1206
32. U. Zeymer, J. Senges, K.G. Parhofer, and J. Rother Risk factors and event rates in patients with atherothrombotic disease in Germany: results of the REACH registry Dtsch Arztebl Int 105 2008 769 775